Clinical Trial Results: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ibrutinib and blinatumomab in relapsed or refractory adult B-ALL, including Philadelphia chromosome-positive cases; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: University of California, Davis | Conditions: Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive | Phase 2 | Status: COMPLETED | Results posted: 2026-06-09